Stay updated on Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.

Latest updates to the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now shows Revision: v3.3.2 instead of v3.3.1, which is a metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check23 days agoChange DetectedA new note explains that Publications are auto-filled from PubMed, and the page revision updated from v3.2.0 to v3.3.1.SummaryDifference0.0%

- Check30 days agoChange DetectedThe location label for site 704 was updated from 'Tainan City, Taiwan, 704' to 'Tainan, Taiwan, 704'. A government funding-status notice text was removed from the page.SummaryDifference0.1%

- Check44 days agoChange DetectedEnrollment is updated to 959 participants and the study's last update is posted on 2025-08-11. Primary completion is 2025-03-20 and estimated study completion is 2025-09-30.SummaryDifference0.1%

- Check73 days agoChange DetectedDifference1%

- Check80 days agoChange DetectedPage content is updated to revision v3.1.0 and several MedlinePlus topics are removed; overall, no substantial new information is added and core content remains unchanged.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.